Through this application, Baylor College of Medicine responds to RFA: CA- 91-35, Specialized Programs Of Research Excellence (SPORE) in Prostate Cancer. Under the leadership of investigators recognized by the externally sponsored support for their current research in prostate cancer, Baylor has organized a team of highly competent scientists to perform innovative research in the biology of prostate cancer and the prevention, diagnosis and treatment of patients with this disease. The scientific program will address translational research issues through the novel mechanism of """"""""working groups"""""""". These multidisciplinary teams of clinical and basic scientists - some principal investigators of research projects, others core directors, some planning future pilot projects, others members of the Internal Advisory Committee - were drawn together by their common interest in one of four focal areas and compose the Clinical Markers, Chemoprevention, Molecular Mechanisms and Endocrine Working Groups. Our strategy will be to focus on the early progression of prostate cancer from its latent to clinical forms. The specific POINTS OF INVESTIGATION are: (1) differentiate stable from unstable forms of latent cancer, and (2) determine the biological factors involved in the rate of progression. The specific POINTS OF INTERVENTION are: (1) Latent Cancer: Use markers to distinguish stable from unstable latent cancer, and develop medical therapy (chemoprevention) to prevent progression from stable to unstable latent cancer, and (2) Early Stage Clinical Cancer: Use new markers to predict the rate of progression and apply therapy appropriate to the risk of the disease. The specific projects and cores included in this program were developed after intensive review by our Scientific Advisory Committee, chaired by Dr. Bert O'Malley, which is responsible for the quality of the science in this program. We have judiciously allocated our budget to reflect our flexible yet focused strategy: 37% assigned among 8 Research Projects, 35% to 5 Core Facilities to support the research and pilot projects, 17% to respond rapidly to new innovative research opportunities through the Developmental Research Program and 11% to Career Development to help produce a new cadre of investigators able to expand the field of translational research in prostate cancer. With a very large and multi-ethnic patient population and with considerable institutional resources committed in space, funds, and personnel, and with a multidisciplinary team with a proven track record of success, Baylor proposes to expand markedly its studies of prostate cancer through this SPORE to bring to the field of translational research in prostate cancer new clinical and basic investigators who, together with the established investigators here, will provide essential new information valuable in our strategic approach to prostate cancer. The purpose of our efforts is ultimately to reduce the incidence and the mortality rate from this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058204-03S2
Application #
2098908
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1992-09-30
Project End
1996-09-29
Budget Start
1994-09-30
Budget End
1996-09-29
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Urology
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Ritz, Anna; Paris, Pamela L; Ittmann, Michael M et al. (2011) Detection of recurrent rearrangement breakpoints from copy number data. BMC Bioinformatics 12:114
Hodgson, Myles C; Shao, Long-jiang; Frolov, Anna et al. (2011) Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71:572-82

Showing the most recent 10 out of 262 publications